Suppr超能文献

[生物标志物在脓毒症中的应用。更新与展望]

[Use of biomarkers in sepsis. Update and perspectives].

作者信息

Siegler B H, Weiterer S, Lichtenstern C, Stumpp D, Brenner T, Hofer S, Weigand M A, Uhle F

机构信息

Klinik für Anaesthesiologie und Operative Intensivmedizin, Universitätsklinikum Gießen und Marburg, Standort Gießen, Rudolf-Buchheim Str. 7, 35392, Gießen, Deutschland.

出版信息

Anaesthesist. 2014 Sep;63(8-9):678-90. doi: 10.1007/s00101-014-2347-2.

Abstract

Sepsis and related complications are a challenge for intensive care medicine. Despite many advances in antibiotic therapy sepsis remains one of the most common diseases of patients in intensive care units and is designated as the main cause of death in critically ill patients. Persisting sepsis leads to impaired immunity, resulting in immunosuppression. Unspecific predictive signs complicate an early diagnosis; however, an early initiation of adequate therapy is of crucial importance for the prognosis. Scoring systems can be applied for the initial evaluation but are controversially discussed concerning the monitoring of disease progression and therapy as well as outcome prediction. Biomarkers are considered as a complementary approach.

摘要

脓毒症及相关并发症是重症医学面临的一项挑战。尽管抗生素治疗取得了许多进展,但脓毒症仍是重症监护病房患者最常见的疾病之一,并且被认定为危重症患者的主要死因。持续性脓毒症会导致免疫功能受损,进而引起免疫抑制。非特异性的预测体征使早期诊断变得复杂;然而,尽早开始充分治疗对预后至关重要。评分系统可用于初始评估,但在疾病进展监测、治疗以及预后预测方面存在争议。生物标志物被视为一种辅助方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验